Standout Papers

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody... 2005 2026 2012 2019 1.4k
  1. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) (2008)
    Craig L. Leonardi, Alexa B. Kimball et al. The Lancet
  2. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) (2008)
    Kim Papp, Richard G. Langley et al. The Lancet
  3. Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease (2012)
    William J. Sandborn, Christopher Gasink et al. New England Journal of Medicine
  4. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial (2005)
    Kristian Reich, Frank O. Nestlé et al. The Lancet
  5. Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis (2013)
    William J. Sandborn, Brian G. Feagan et al. Gastroenterology
  6. Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis (2010)
    C.E.M. Griffiths, Bruce Strober et al. New England Journal of Medicine
  7. A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis (2007)
    Gerald G. Krueger, Richard G. Langley et al. New England Journal of Medicine
  8. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial (2005)
    Christian Antoni, Gerald G. Krueger et al. Annals of the Rheumatic Diseases
  9. Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis (2013)
    William J. Sandborn, Brian G. Feagan et al. Gastroenterology

Immediate Impact

15 by Nobel laureates 12 from Science/Nature 129 standout
Sub-graph 1 of 14

Citing Papers

Ulcerative Colitis in Adults
2023 Standout
Ulcerative colitis
2023 Standout

Works of Cynthia Guzzo being referenced

Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2013 Standout
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
2013 Standout

Author Peers

Author Last Decade Papers Cites
Cynthia Guzzo 8580 3841 2611 2666 83 12.1k
Craig L. Leonardi 11088 6216 692 2559 130 13.7k
Roza Nurieva 14150 916 1171 1026 74 17.3k
Xuexian O. Yang 12169 1012 1055 935 59 15.6k
Gordon W. Duff 5082 787 1237 1966 139 13.1k
Gerald G. Krueger 7427 3515 533 3062 119 9.6k
Edward P. Bowman 6899 1910 482 1639 50 9.6k
Kerstin Wolk 6162 3370 534 647 104 10.0k
Helgi Valdimarsson 4963 2127 333 1535 171 8.0k
Lorenzo Cosmi 7419 823 699 840 131 12.2k
S. Aractingi 2950 2092 526 1187 254 6.9k

All Works

Loading papers...

Rankless by CCL
2026